↓ Skip to main content

Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression

Overview of attention for article published in Molecular Therapy, September 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
3 tweeters
patent
8 patents
facebook
1 Facebook page

Citations

dimensions_citation
73 Dimensions

Readers on

mendeley
53 Mendeley
Title
Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression
Published in
Molecular Therapy, September 2012
DOI 10.1038/mt.2012.83
Pubmed ID
Authors

Omar D Perez, Christopher R Logg, Kei Hiraoka, Oscar Diago, Ryan Burnett, Akihito Inagaki, Dawn Jolson, Karin Amundson, Taylor Buckley, Dan Lohse, Amy Lin, Cindy Burrascano, Carlos Ibanez, Noriyuki Kasahara, Harry E Gruber, Douglas J Jolly

Abstract

Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor cells fit both these descriptions. Previous publications have described a prototype based on an amphotropic murine leukemia virus (MLV), encoding yeast cytosine deaminase (CD) that converts the prodrug 5-fluorocytosine (5-FC) to the potent anticancer drug, 5-fluorouracil (5-FU) in an infected tumor. We report here the selection of one lead clinical candidate based on a general design goal to optimize the genetic stability of the virus and the CD activity produced by the delivered transgene. Vectors were tested for titer, genetic stability, CD protein and enzyme activity, ability to confer susceptibility to 5-FC, and preliminary in vivo antitumor activity and stability. One vector, Toca 511, (aka T5.0002) encoding an optimized CD, shows a threefold increased specific activity in infected cells over infection with the prototype RRV and shows markedly higher genetic stability. Animal testing demonstrated that Toca 511 replicates stably in human tumor xenografts and, after 5-FC administration, causes complete regression of such xenografts. Toca 511 (vocimagene amiretrorepvec) has been taken forward to preclinical and clinical trials.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 52 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 30%
Student > Ph. D. Student 10 19%
Student > Bachelor 9 17%
Student > Master 7 13%
Other 4 8%
Other 6 11%
Unknown 1 2%
Readers by discipline Count As %
Agricultural and Biological Sciences 22 42%
Immunology and Microbiology 7 13%
Biochemistry, Genetics and Molecular Biology 6 11%
Medicine and Dentistry 6 11%
Engineering 3 6%
Other 6 11%
Unknown 3 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2019.
All research outputs
#1,634,948
of 13,304,005 outputs
Outputs from Molecular Therapy
#593
of 3,136 outputs
Outputs of similar age
#14,669
of 121,073 outputs
Outputs of similar age from Molecular Therapy
#7
of 49 outputs
Altmetric has tracked 13,304,005 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,136 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,073 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.